-
Signature
-
/s/ Tobin Schilke, as attorney-in-fact
-
Issuer symbol
-
CRNX
-
Transactions as of
-
20 Aug 2025
-
Net transactions value
-
-$189,437
-
Form type
-
4
-
Filing time
-
21 Aug 2025, 16:30:04 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Pizzuti Dana |
Chief Med and Dev Officer |
C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO |
/s/ Tobin Schilke, as attorney-in-fact |
21 Aug 2025 |
0001948238 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
CRNX |
Common Stock |
Sale |
$189,437 |
-6,492 |
-8.9% |
$29.18 |
66,270 |
20 Aug 2025 |
Direct |
F1, F2, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: